cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2014-1-4-7cardiovascular-1Research ArticleПЕРЕДОВАЯ СТАТЬЯEDITORIALДОСТИЖЕНИЯ И НЕУДАЧИ В ПРОФИЛАКТИКЕ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙSUCCESSES AND FAILURES OF CARDIOVASCULAR PREVENTIONОгановР. Г.OganovR. G.
руководитель отдела профилактики коморбидных состояний, главный научный сотрудник
gmaslennikova@gnicpm.ruМасленниковаГ. Я.MaslennikovaG. Ya.
ведущий научный сотрудник отдела
gmaslennikova@gnicpm.ruГосударственный научно-исследовательский центр профилактической медицины Минздрава России, МоскваState Research Centre for Preventive Medicine. Moscow, Russia20142002201413147Copyright © Оганов Р.Г., Масленникова Г.Я., 20142014Оганов Р.Г., Масленникова Г.Я.Oganov R.G., Maslennikova G.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1
.
.
сердечно-сосудистые заболеванияфакторы рискастратегия профилактикипарадоксы в профилактикеcardiovascular diseaserisk factorspreventive strategyprevention paradoxesReferencesOganov RG. Failed expectations and paradoxes of preventive cardiology. Cardiovascular Therapy and Prevention 2009; 8 (7):4–10 (Оганов Р. Г. Несбывшиеся надежды и парадоксы профилактической кардиологии. Кардиоваскулярная терапия и профилактика 2009; 8 (7):4–10).Oganov RG. Failed expectations and paradoxes of preventive cardiology. Cardiovascular Therapy and Prevention 2009; 8 (7):4–10 (Оганов Р. Г. Несбывшиеся надежды и парадоксы профилактической кардиологии. Кардиоваскулярная терапия и профилактика 2009; 8 (7):4–10).www.who.int/healthinfo/statistics/mortality/enwww.who.int/healthinfo/statistics/mortality/enFord ES, Ajani UA, Croft JB, et al. Expanding the Decrease in the U. S. Deaths from Coronary Dissease, 1980–2000. The New Engl J Med 2007; 256 (23): 2388–98.Ford ES, Ajani UA, Croft JB, et al. Expanding the Decrease in the U. S. Deaths from Coronary Dissease, 1980–2000. The New Engl J Med 2007; 256 (23): 2388–98.Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales, 1981–2000. Circulation 2004; 109: 1101–7.Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales, 1981–2000. Circulation 2004; 109: 1101–7.Rose G. Sick individuals and sick populations. Internat J Epidemiology 1985; 14: 32–8.Rose G. Sick individuals and sick populations. Internat J Epidemiology 1985; 14: 32–8.Grodstein F, Stampher MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and their risk of cardiovascular. N Engl J Med 1996; 335:453–61.Grodstein F, Stampher MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and their risk of cardiovascular. N Engl J Med 1996; 335:453–61.Bath P, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330:432.Bath P, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330:432.Beral V, Banks E, Reeves G. Evidence from randomized trials on long-term effects of hormone replacement therapy. Lancet 2002; 360:942–4.Beral V, Banks E, Reeves G. Evidence from randomized trials on long-term effects of hormone replacement therapy. Lancet 2002; 360:942–4.Peverill R. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 2002; 17:149–64.Peverill R. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 2002; 17:149–64.Gratsiansky NA. Although evidences for the use of hormone replacement therapy with estrogen are existed, whereas CHD prevention is not among them. Cardiology 2000;6: 23. Russian (Грацианский Н. А. Если и существуют показания для применения гормональной заместительной терапии эстрогенами, то предупреждение КБС в их число пока не входит. Кардиология 2000; 6: 23).Gratsiansky NA. Although evidences for the use of hormone replacement therapy with estrogen are existed, whereas CHD prevention is not among them. Cardiology 2000;6: 23. Russian (Грацианский Н. А. Если и существуют показания для применения гормональной заместительной терапии эстрогенами, то предупреждение КБС в их число пока не входит. Кардиология 2000; 6: 23).Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. JACC 2009; 53:1925–32.Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. JACC 2009; 53:1925–32.Ades PA, Savage PD. The obesity paradox: perception vs knowledge. Mayo Clin Proc 2010; 85:112–4.Ades PA, Savage PD. The obesity paradox: perception vs knowledge. Mayo Clin Proc 2010; 85:112–4.Badheka AO, Rathold A, Kizibash, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 2010; 123:646–51.Badheka AO, Rathold A, Kizibash, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 2010; 123:646–51.Continho T, Goel K, Correa de Sa D, et al. Central obesity and survival in subjects with CAD: a systematic review of the literature and collaborative analysis utilizing individual subjects data. JACC 2011; 57:1877–86.Continho T, Goel K, Correa de Sa D, et al. Central obesity and survival in subjects with CAD: a systematic review of the literature and collaborative analysis utilizing individual subjects data. JACC 2011; 57:1877–86.Bays HE. Adiposopathy is “Sick Fat” a Cardiovascular Disease? JACC 2011; 57:2461–73.Bays HE. Adiposopathy is “Sick Fat” a Cardiovascular Disease? JACC 2011; 57:2461–73.Kallikazaros I. E. Obesity:”Less is more”. Hellenic J Cardiol 2013; 54:333–6.Kallikazaros I. E. Obesity:”Less is more”. Hellenic J Cardiol 2013; 54:333–6.Barbash GI, Reiner J, White HD, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the “smoking paradox” from the GUSTO-I trial with angiographic insights. JACC 1995; 26:1222–9.Barbash GI, Reiner J, White HD, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the “smoking paradox” from the GUSTO-I trial with angiographic insights. JACC 1995; 26:1222–9.Hasadi D, Lerman A, Rihal ES, et al. Smoking status and outcome after primary angioplasty for acute myocardial infarction. Am Heart J 1999; 137:612–20.Hasadi D, Lerman A, Rihal ES, et al. Smoking status and outcome after primary angioplasty for acute myocardial infarction. Am Heart J 1999; 137:612–20.Ovbiagele B, Saver JL. The smoking-thrombolysis paradox and acute ischemic stroke. Neurology 2005; 65:293–5.Ovbiagele B, Saver JL. The smoking-thrombolysis paradox and acute ischemic stroke. Neurology 2005; 65:293–5.Suskin N, Pipe A, Prior P. Smokers paradox or not in heart failure, just quit. Eur Heart J 2008; 29:1932–3.Suskin N, Pipe A, Prior P. Smokers paradox or not in heart failure, just quit. Eur Heart J 2008; 29:1932–3.Elwood PC, Pickeriog JE, Givens DI, Gollacher JE. The consumption of milk and dairy foods and the incidence of vascular disease and diabetes: an overview of the evidence. Lipids 2010; 45:925–39.Elwood PC, Pickeriog JE, Givens DI, Gollacher JE. The consumption of milk and dairy foods and the incidence of vascular disease and diabetes: an overview of the evidence. Lipids 2010; 45:925–39.Rong Ying, Chen Li, Zhu Tingting, et al. Egg consumption and risk of coronary heart disease and stroke: dose response meta-analysis of prospective cohort studies. BMJ 2013: e 8539.Rong Ying, Chen Li, Zhu Tingting, et al. Egg consumption and risk of coronary heart disease and stroke: dose response meta-analysis of prospective cohort studies. BMJ 2013: e 8539.
The authors declare that there are no conflicts of interest present.